Podcasts about assistant attending physician

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of zenocutuzumab for NSCLC with an NRG1 fusion. NRG1 fusions are rare but important events seen in many cancer types, including NSCLC. Zenocutuzumab is a HER2/HER3 bispecific antibody that showed clear efficacy in NSCLC and in pancreatic cancer that harbored an NRG1 fusion. Guest: Dr. Alison Schram, Assistant Attending Physician and Section Head of Oral Therapeutics in Early Drug Development at Memorial Sloan Kettering Cancer Center in New York

Wear and tear on our active joints is inevitable, and the menopause transition can make them more vulnerable. But there are some simple, and often overlooked, ways to support our joint health that include proper nutrition, recovery, strength and mobility practices, footwear and more, which can help us stay active and pain free through and beyond menopause. This week we break it all down with sports medicine physician Dr. Ashley Austin.Ashley V. Austin, MD, is Assistant Attending Physician at the Hospital for Special Surgery. She graduated cum laude from the University of Evansville where she played Division I basketball and was an all-conference offensive and defensive player. Dr. Austin completed her family medicine residency at the University of Virginia and completed a fellowship in primary care sports medicine at the University of Washington (Seattle, WA). After fellowship, she remained on faculty at the University of Washington as an Assistant Professor. She also served as the Co-Director of Musculoskeletal Anatomy and Physiology for the School of Medicine and Faculty Liaison for Equity, Diversity, and Inclusion in the Department of Family Medicine. Dr. Austin has covered sports at all levels including high school, National Ski Patrol, the WNBA and MLB. Her hobbies include high-altitude mountaineering and hiking, playing tennis, basketball, and soccer, snowboarding, and learning to surf. You can learn more about her and her work at www.hss.edu.Register for the Feisty Summer STRONG Course: https://www.womensperformance.com/strong Subscribe to the Feisty 40+ newsletter: https://feistymedia.ac-page.com/feisty-40-sign-up-page Follow Us on Instagram:Feisty Menopause: @feistymenopause Feisty Media: @feisty_media Selene: @fitchick3 Hit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099 Join Level Up - Our Community for Active Women Navigating the Menopause Transition:Join: https://www.feistymenopause.com/monthly-membership-1 Leave your questions for Selene:https://www.speakpipe.com/hitplay Get the Free Feisty Women's Guide to Lifting Heavy Sh*t:https://www.feistymenopause.com/liftheavy Support our Partners:Previnex: Get 15% off your first order with code HITPLAY at https://www.previnex.com/ Lagoon Sleep: Go to LagoonSleep.com/hitplay and take the 2 minute sleep quiz to find your match, and then use the code HITPLAY for 15% off your first purchase

JCO PO author Dr. Alicia Latham shares insights into her JCO PO article, “Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome.” Host Dr. Rafeh Naqash and Dr. Latham discuss microsatellite instability-high status as well as familial risk and testing. Click here to read the article! TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology, and Assistant Professor at the OU Stephenson Cancer Center.  Today we are excited to be joined by Dr. Alicia Latham, Medical Director at the Memorial Sloan Kettering-CATCH, and the Assistant Attending Physician, General Internal Medicine and Clinical Genetics. Dr. Latham is also the author for our JCO Precision article titled "Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome."  At the time of this recording, our guest on this podcast had no disclosures.  Dr. Latham, thank you so much for joining us today, and welcome to our podcast. Dr. Alicia Latham: Very happy to be here today. Thank you for inviting me. Dr. Rafeh Naqash: For the sake of this podcast, we'll refer to each other using our first names if that's okay with you. Dr. Alicia Latham: Sure. Dr. Rafeh Naqash: So this is a very interesting, broad topic that I wanted to discuss with you, and hopefully, our listeners find it very interesting. It touches on a broad range of currently relevant precision medicine-related topics, which is mismatch repair deficiencies, colorectal cancers, and Lynch syndrome. Could you try to give us an understanding of what we know so far about colorectal cancers that are mismatched repair deficient as well as Lynch syndrome, which would be, hopefully, an interesting segue into your article? Dr. Alicia Latham: Sure. In general, I think when speaking of mismatch repair deficiency in the setting of colorectal cancer, we know that the vast majority of the time it's somatically driven, not necessarily that there was an inherent genetic predisposition that drove it, and we've known that for quite some time. But the issue is that there's still about 15% of the time or so when you're looking at colon cancers, that a germline component is probably driving that mismatch repair deficiency, i.e. Lynch syndrome. And that became exceptionally relevant whenever universal screening for said tumors was occurring as a way to screen for Lynch syndrome. And even perhaps more importantly, with the usage and increasing usage of immune checkpoint blockade because we know that those cancers respond exquisitely well because of that driver. And in terms of our understanding, typically because patients with Lynch syndrome inherently have a defect in mismatch repair, their tumors, pan-cancer, which we published on previously in JCO, demonstrate mismatch repair deficiency or MSI high status, if that was contributed.  So really the point of looking at this was to take that initial work and kind of turn it on the flip side. And rather than assessing all tumors for MMRD status or MSI high status, to look at colorectal cancer tumors at our institution, find the underlying prevalence of Lynch syndrome, and then see how many presented with a mismatch repair proficient tumor and what that may or may not imply or mean for the patient clinically. That was really the whole point. Dr. Rafeh Naqash: Excellent, thank you so much for the explanation. Now, I do remember when I was a fellow in my first-year fellowship, I would often get confused, and I think NGS was just becoming the thing of the day a couple of years back, especially for metastatic tumors. I would often get confused between MMR deficiency and MSI high. And for trainees who are going to start in a week or so into their fellowships, who hopefully will be listening to this, could you give us a simpler version of how you would explain to a new trainee what MMR deficiency versus MSI high is? Dr. Alicia Latham: Sure. So we'll start with MMR deficiency. So IHC or immunohistochemical analysis has been around for a while. That's kind of your classic way of assessing for this. And really what that means is that when the tumor is stained for the mismatch repair proteins, they're found to be deficient, meaning that one or more of said proteins is not expressed in the tumor. So that's mismatch repair deficiency. Usually, the staining patterns have a very unique pattern to them, meaning that you'll typically see MLH1 and PMS2 absence go together, or MSH6 and MSH2 absence go together. They go hand in hand. I call it the “buddy system.”  Microsatellite instability - before defining what that means, I think it's important to explain what microsatellites themselves are. And so when I talk to trainees, I say microsatellites are just little repeat sequences throughout our genome that are kind of little “bookmarks.” And our mismatch repair system finds those little repeat sequences to try to look for errors, spelling errors. That's the spell checker of the mismatch repair. And so it scans, finds a bookmark, reads to see if there's a mismatch. If there is, it corrects it and then goes to the next one, and so on and so forth.  Over time, if those mismatches aren't repaired, then you may see a discrepancy in the now cancerous tissue versus the normal. And that is what's called microsatellite instability, meaning that the tumor, the variance in those repeat sequences is different in the tumor versus the normal tissue. They typically have a concordance rate of greater than 90%. Dr. Rafeh Naqash: So basically, in your practice, do you often do, and I know you've touched upon some of the overlapping incidences in your paper, but do you, in your practice, do MSI testing using NGS and IHC testing on all patients that need to be tested? Dr. Alicia Latham: So it depends on how they get to us. By the time patients have gotten to genetics, usually at MSK because we have this institutional protocol, MSK-IMPACT, these patients are offered paired NGS sequencing, so tumor-normal sequencing, and they can either consent to just somatic profiling, or somatic and germline. And so by the time we see them, our NGS profile uses MSIsensor for categorization of the MSI status. So they usually have that.  But if there's any discordance or surprising feature, say the patient comes in, their tumor is MSS but the patient has a known MLH1 germline mutation and the family history looks striking for Lynch syndrome, that's suspicious. So we'll do an orthogonal method to look at the tumor, usually starting with IHC to see if it's mismatch repair deficient because that's very easy to do. And then we can also have an additional analysis that's in the process of going through clinical validation called MiMSI, which is essentially an algorithm that has been trained as a machine learning tool on the original impact data and MSIsensor that has a higher clinical validity in tumors that have low tumor content. So MSIsensor is known to have a bit of a flaw in that in tumors with less than 10% of tumor content in the sample, that it may be artificially low. So that's why we also look at that too. So we typically do, if we're suspicious, we'll do an additional method. Dr. Rafeh Naqash: Interesting. Now, going to this interesting work that you published in JCO PO, it seems the premise is more or less around understanding what percentage of patients with Lynch syndrome have mismatch repair proficient colorectal cancers that could be driven by other sporadic changes, genomic changes, or whatever factors that could be, perhaps, leading to tumorigenesis. So was that how you started this project? Or were you trying to answer a different question but understood that this could be a very clinically relevant or meaningful question also? Dr. Alicia Latham: Honestly, how this came about was we had our first patient come in with- had known Lynch Syndrome and had a proficient tumor. And what brought up the question about it as to why it was clinically relevant is one, they were considering immunotherapy, and the oncologist was like, “Do I or do I not do this?” And then the second question is: well, what does this necessarily mean for the family? If this tumor is truly mismatch repair proficient, does that mean that the Lynch syndrome caused it, and so, therefore, someone that tests negative, or deficient, someone who tested negative for the Lynch syndrome, may be off the hook for screening? Or if it's truly proficient, does that family member now have a familial risk for colon cancer and should perhaps consider increased screening? So those were the clinical questions that came up in that case.  And because of that case, that was like, well, how many times does this really happen? Has anybody published on this yet? And we didn't see anything at the time, and we had this large impact data cohort. So we decided to dive a little bit deeper and see what we can find. It is rare, but it happens. Dr. Rafeh Naqash: You bring this very interesting point that some of the very clinically relevant projects or research, it stems from a unique clinical patient scenario where you saw an individual, you tried to understand why, and you took it to the next step. In fact, I do drug development, Phase 1 clinical trials, and I have an individual with a history of Lynch syndrome and germline positive with osteosarcoma but mismatch repair proficient. And before reading this paper, I've come across some other data. In the Phase I setting when you don't have a target, your next best option is to go for immunotherapy--novel immunotherapy-based approaches. And in this individual, I was debating whether an immunotherapy approach would be reasonable or not. But based on the data and then looking at your paper, I am less convinced that with a mismatch repair proficient tumor, because in the standard care setting, obviously, immune checkpoint inhibitors have an indication for tumor MSI high, not germline. So these are rare, but when they happen, it does bring into question, like you said, implications for the family, whether or not immunotherapy is a relevant option in those individuals. So, very, very important to understand this.  So could you tell me, and the listeners also, walk us through the data set that you looked at? What was the denominator and how did you end up with the sample size that helped you understand this topic? Dr. Alicia Latham: Sure. So we first started with just looking at our overall MSK IMPACT cohort at the time that had undergone germline or analysis of their DNA. And so that was over, at the time, 17,000 cases. Then looking at those, we wanted to understand and assess the underlying Lynch syndrome prevalence of all of those cases. So overall, it was 17,617 pan-cancer patients. And we found, of those, about a 1.5% prevalence of Lynch syndrome pan-cancer. And then of those we assessed, of those patients with known Lynch syndrome, how many had at least one colorectal tumor that underwent that NGS profiling, and that came out to about 36% or 86 cases.  Of course, because Lynch syndrome is known to have synchronous and metachronous tumors, there were a few patients that had more than one colorectal cancer assessed, so it actually ended up being 99 pooled tumors. So then you're looking at 99 pooled tumors there of those Lynch syndrome cohorts, of which about roughly 10% were found to be mismatch repair proficient, and they were also MSS or microsatellite stable by MSIsensor. So that was how we broke it down. Dr. Rafeh Naqash: Interesting. Now, looking through your manuscript, I understood that you identified some unique differences between the mismatch repair proficient Lynch syndrome-positive individuals and mismatch repair deficient individuals in the cohort. What were some of the highlights of the different clinical characteristics that could be clinically meaningful? Dr. Alicia Latham: Sure. So I think one of the most important things, at least from a genetics perspective, was we did find an enrichment among the mismatch repair proficient group of those having either an MSH6 or PMS2 germline variant. And that's notable because those are known to be kind of our lower-risk genes. And in fact, oftentimes patients and families don't meet typical clinical criteria for genetic testing in those families. So PMS2 is probably the most obvious case of that where the families don't really look suggestive of classic Lynch syndrome. That was significant even in a small cohort, so it was 89% of patients with mismatch repair proficient tumors had MSH6 or PMS2 mutations.  The other, while it didn't quite achieve statistical significance simply because it was a small cohort, the age of onset was different. So mismatch repair proficient, they were a little bit older. Our median age of onset was 58 in that group and then the mismatch repair deficient group median age was 43%. So I think if we had a larger sample size that would achieve statistical significance there.  The other important caveat was just kind of when they presented, what stage did they present at. So, unfortunately, we did see a higher prevalence of patients presenting with metastatic disease in our mismatch repair proficient group. And that makes sense because if these are patients that are typically with Lynch syndrome, that is perhaps a milder phenotype if you will, maybe they weren't identified early enough because the family histories weren't suggestive. So they weren't undergoing high-intensity surveillance compared to those that were in the mismatch repair deficient group that had the higher risk genes. And likely their family histories met clinical criteria for Lynch syndrome. Dr. Rafeh Naqash: Thank you so much. Now, the number that stands out in your manuscript is 10%--with individuals that had Lynch Syndrome and having mismatch repair proficient colorectal cancers. In your tumor boards that you perhaps participate in with GI, medical oncology, or other multidisciplinary tumor boards, do you try to discuss some of this early on so that implementation and uptake of whether it's NGS or germline testing is high right from the get-go? Do you try in your tumor boards to suggest to the treatment team that they should have perhaps germline testing also before they see you or at least have ordered it by the time they see you and also a full NGS panel? Or is that something that's just routinely done at your cancer center? Dr. Alicia Latham: It's routinely done at MSK. We are fortunate because of the MSK IMPACT protocol that they are routinely done. Having said that, if there is any sort of question, like I said before, oftentimes we'll talk to the oncologist about doing an orthogonal method just to verify. We also have patients that come from outside and maybe they've already had some sort of initial screening and so they wouldn't necessarily be candidates with insurance criteria, etc., for additional assessment. So we have to get a little bit creative in terms of our workup and how we can help those patients as well. But yes, we typically do. If you're suspicious, yes, we do recommend it. Dr. Rafeh Naqash: Excellent. And I know, I think, with more and more precision oncology coming up, I was speaking with a few other clinical geneticist experts at ASCO, I think incorporating individuals with clinical genomics and genetics expertise like yourself, incorporating those individuals into tumor boards, not just molecular tumor boards, but the multidisciplinary tumor boards early on, I think, could make an impact as far as testing is concerned and as far as identifying some of these things early on is concerned.  Now I would like to ask you an interesting, provocative question that you necessarily haven't addressed in the paper, but it is nevertheless interesting. So when you found or you mentioned that some of these genes have different penetrants or some are higher risk in the MSI group, the mismatch repair deficient genes, or when you think about DNA damage response, you think about neoantigens, which goes into the context of immune checkpoint inhibitors. Has there been any data or what would you think from a perspective of whether a certain gene has a higher neo antigen burden associated with it, meaning a higher number of antigens that are necessarily something that the immune system thinks that they're foreign, which helps immune checkpoint inhibitors to work? So do you think there is a difference from a neoantigen perspective in these genes suggesting that a certain tumor with a PMS deficiency versus another tumor with an MSH6 deficiency have different responses or outcomes to immune checkpoint therapy? Dr. Alicia Latham: My gut tells me perhaps. We know that when you're looking at different tumors for their MSI status or their MMR status, that MSH6, for example, mutation carriers, seem to have lower levels of that. So even just looking at our MSIsensor scores in general, they tend to be lower for MSH6 mutation carriers. So to me that signal, if it's not as pronounced, you would think that perhaps that's also there. And I think other groups have looked at that, that you're seeing that. As far as clinical response, I don't know if you're, in terms of comparing tumor to tumor, if they have the same profile, I would suspect that the response would be similar. Of course, if there's something varied, then I think that whichever profile has that higher tumor mutation burden or those neoantigens would respond better.  But I think at least as a non-oncologist, as a geneticist, and someone who's very interested in prevention, I think it's something that is incredibly important for the vaccine trials that are going on to understand and making sure that patients that we are recruiting to these trials have PMS2 and MSH6 associated Lynch syndrome, that we're not just focusing on those that we know have higher tumor mutation burden or MSI status because those are the patients we want to make sure that we're including in designing those and targeting the appropriate antigens for those trials because that is very important work that I know colleagues at other institutions are working on diligently. Dr. Rafeh Naqash: I think those are very interesting thoughts and perhaps somebody in the near future will address some of these interesting concepts.  One of the things that I didn't see in the paper that we are discussing today is what were the potential somatic, tumor somatic, events in the mismatch repair proficient colorectal cancers in the 10% that you identified that could have led to their tumor genesis. Did you look into that? Is there any subsequent work that is going on in that space? Dr. Alicia Latham: Yeah, we are looking at it subsequently, we didn't for the content of this paper. We were really focused on the MSI and mismatch repair proficiency. But yes, there was actually a study that is assessing this - really more of a pan-cancer study. We started here and one of my colleagues at MSK is working on looking at this pan-cancer and trying to understand these orthogonal methods, the tumor somatic drivers. They actually presented this abstract at ASCO this year. So trying to understand what actually did drive this. And is that something in terms of treatment that we need to be very much aware of? And I think the answer is ‘yes.' So more to come on. Dr. Rafeh Naqash: That's excellent. So hopefully, we'll see something in that space from your group in the coming months.  Another question you touched upon earlier is the implications for familial testing. So if an individual, for the sake of our listeners, if an individual comes to my clinic tomorrow with a mismatch repair proficient tumor but with a Lynch syndrome history, something similar to that I described earlier for my patient with sarcoma, what would the counseling be from a geneticist standpoint for the family? How would you explain the risk? How would you explain the tumor in that individual and then testing for the family members? Dr. Alicia Latham: So regardless of what the tumor demonstrated, I think it would be important, if this is a known Lynch syndrome patient, explaining to close family members that they have a risk of having this, a first-degree family member's 50% chance of sharing the mutation. And that's important regardless of what the tumor shows. Where I think it's more of the nuance is explaining to particularly those patient family members that test negative for Lynch syndrome. For example, in colon cancer, we say that if you have a first-degree relative with colon cancer, that, regardless of the looks like familial colon cancer without a genetic explanation, that you start colonoscopies a little sooner and you do them more frequently. So rather than 45, you start at around age 40, rather than every ten years, you repeat every five. Of course, if polyps appear, that's altered.  And so because we don't quite know if a mismatch repair colon cancer was really driven by that germline, say PMS2 mutation, could this in fact be a sporadic colon cancer that's incidental to the PMS2 mutation? Therefore, that family member that tests negative may be at an elevated risk of colon cancer and may want to consider doing colonoscopies a little sooner and a little more frequently. Having said that, I think that it's a very important conversation to have with the family members to make sure that they are very clear on that. But I think that there's a lot of work that needs to be done to understand - is it truly the case? Is there any role at all? What can we use as far as understanding kind of a different pathway for certain mutation carriers like MSH6 and PMS2? Is there something else that we're missing? So for now, I counsel my patients that I would recommend, even if you test negative, to screen a little bit earlier and a little more frequently until we understand this a little better. Dr. Rafeh Naqash: Thank you so much for that explanation. And this was a very interesting opportunity for me to help take a deeper dive into this paper, hopefully for our listeners as well. Now, a few questions about yourself, Alicia. So we like to know a little bit about the individual or individuals behind the work. So tell us a little bit about your training and your current interests and also what advice you have for early pre-investigators in the space of precision medicine, the way it's developing right now.  Dr. Alicia Latham: Sure. My training is a little bit unique, so I'm not a medical oncologist by training. I knew that I wanted to be on the prevention side, not necessarily the treatment side because when I was in medical school what was available was chemotherapy. And that wasn't for me. I didn't want to do that. And so I trained in family medicine and then completed a fellowship in medical genetics with a focus on cancer. And my clinical focus is really taking care of patients with a genetic predisposition, so at-risk patients. In that regard, I serve as Medical Director for our program at MSK called MSK CATCH, which is really for patients that have a germline susceptibility of cancer, but they want to be followed and managed at Sloan. So that's my clinical focus.   And then my research is really looking at germline predisposition, primarily Lynch syndrome, to try to understand what do we know and more importantly, what don't we know about this pan-cancer syndrome and how can we help these patients and families. Many of my studies have looked at that from understanding descriptively Lynch syndrome among different types of cancer, like small bowel cancer or the MSI status pan-cancer paper. But importantly, where we're going in the future and where I am going in the future is looking at where can we go to early detection in these patients and really increase screening because right now, the only proven effective screening for Lynch syndrome is colonoscopy, and yet it's a pan-cancer syndrome. So we have a lot of work to do. Dr. Rafeh Naqash: Thank you so much. It was really awesome to talk to you today. And thanks for explaining some of the interesting concepts around MSI-high colorectal cancers and Lynch syndromes. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Guest Biography: Dr. Alicia Latham is Medical Director at Memorial Sloan Kettering-CATCH and Assistant Attending Physician, General Internal Medicine and Clinical Genetics COIs: none  

Obesity is a disease. It's not just a lifestyle issue.   Jason A. Duprat, Entrepreneur, Healthcare Practitioner, and Host of the Healthcare Entrepreneur Academy podcast, sits down with Katherine Saunders, Co-Founder of Intellihealth, Diplomat of the American Board of Internal Medicine and the American Board of Obesity Medicine, and Host of the Weight Matters Podcast. Join us in this episode as we debunk the long-standing stigma surrounding obesity and learn more about Katherine and Intellihealth's mission to bring accessible medical obesity care for all.   EPISODE HIGHLIGHTS  Serving as a Primary Care physician, Katherine was overwhelmed with her patients' weight-related diseases which inspired her to pursue Obesity Medicine. Katherine's mentor had a predecessor company which she and her husband transitioned into Intellihealth, wherein they aim to democratize effective obesity treatment. Science and research show that obesity is a disease and not just a lifestyle issue. Physiological and pathophysiological changes occur with excess weight that make it very difficult to lose weight and easy to gain weight. Obesity Medicine is a newer field of medicine. There are only under 6,000 physicians who are certified in Obesity Medicine, which is astoundingly low considering how rampant obesity is in America. The cornerstone of the field is dietary strategies, physical activity, and behavioral change. Medications come in only after comprehensive evaluations and needs assessments. Katherine mentions the American Board of Obesity Medicine, Obesity Medicine Associate, and conferences available to learn more about the field. She works closely with Software Developers in Intellihealth, combining two vastly different fields to make Obesity Medicine more accessible for all. One of their goals is to break the stigma, to educate people that obesity is a disease and not dependent on willpower alone. JOIN OUR GIVEAWAY! Get a chance to win a FREE 30-DAY VIP access to Jason Duprat via Voxer! Be one of the 5 lucky winners to win a strategy call with Jason where he answers all your burning questions about your healthcare business. To join the podcast giveaway, follow these 3 easy steps:   *Step 1: Leave a review for The Healthcare Entrepreneur Academy Podcast on https://lovethepodcast.com/hea *Step 2: Take a screenshot of your review/rating. *Step 3: Submit the screenshot through this form: https://bit.ly/HEAGIVEAWAY.   …and you're done! FIVE lucky winners will be selected at random and announced through the Healthcare Entrepreneur Academy Facebook group and the newsletter!   3 KEY POINTS Obesity is a disease and not just a lifestyle issue. Medicine and Technology work hand-in-hand in bringing healthcare to the world. One of Obesity Medicine's goals is to break the stigma around it.   TWEETABLE QUOTES  “Obesity is a disease. It's not just a lifestyle issue.” – Katherine Saunders “When you factor in how fast technology is evolving, the future of medicine is extremely bright.” – Jason Duprat   RESOURCES Want to become a Ketamine Therapy provider? Enroll NOW in The Ketamine Academy course: ketamineacademy.com/presentation Have a healthcare business question? Want to request a podcast topic? Text me at 407-972-0084 and I'll add you to my contacts. Occasionally, I'll share important announcements and answer your questions as well. I'm excited to connect with you! Do you enjoy our podcast? Leave a rating and review: https://lovethepodcast.com/hea  Don't want to miss an episode? Subscribe and follow: https://followthepodcast.com/hea    ABOUT THE GUEST Katherine Saunders, MD, is an Assistant Attending Physician at New York-Presbyterian Hospital and hosts the Weight Matters podcast. She is also the Co-Founder of Intellihealth, an organization that provides technology to help healthcare systems provide medical obesity care. Katherine specializes in the care of patients with obesity and weight-related medical complications. Her areas of expertise include advanced medical approaches to obesity and strategies to counteract medication-induced weight gain.   CONNECT WITH THE GUEST LinkedIn: https://www.linkedin.com/in/katherine-saunders-711a8122/ Co-founded Company (Intellihealth) https://www.intellihealth.co/ Clinical Services for Medical Obesity Treatment (Flyte) https://www.intellihealth.co/flyte/about-flyte/ Podcast (Weight Matters) - https://www.intellihealth.co/podcast/   #HealthcareEntrepreneurAcademy #healthcare #HealthcareBoss #entrepreneur #entrepreneurship #podcast #businessgrowth #teamgrowth #digitalbusiness

  On PopHealth Week, our guests are Weill Cornell Medicine faculty: Dr. Louis Aronne and Dr. Katherine Saunders, co-founders of Intellihealth, a company fighting the global obesity epidemic. They also host the podcast Weight Matters. Louis J. Aronne, MD, FACP is the Director, Comprehensive Weight Control Center,Weill Cornell Medicine and Past Chairman, American Board of Obesity Medicine. Katherine H. Saunders, MD, DABOM is an Assistant Professor of Clinical Medicine at Weill Cornell Medicine and an Assistant Attending Physician at New York-Presbyterian Hospital. Do follow their work on Twitter via @ljaronne and @Intellihealth1 and on the web at Comptehensive Weight Control Center or atIntellihealth. ==##==  

On PopHealth Week, our guests are Weill Cornell Medicine faculty: Dr. Louis Aronne and Dr. Katherine Saunders, co-founders of Intellihealth, a company fighting the global obesity epidemic. They also host the podcast Weight Matters. Louis J. Aronne, MD, FACP is the Director, Comprehensive Weight Control Center, Weill Cornell Medicine and Past Chairman, American Board of Obesity Medicine. Katherine H. Saunders, MD, DABOM is an Assistant Professor of Clinical Medicine at Weill Cornell Medicine and an Assistant Attending Physician at New York-Presbyterian Hospital. Do follow their work on Twitter via @ljaronne and @Intellihealth1 and on the web at Comptehensive Weight Control Center or at Intellihealth. ==##==

Free CME and NCPD credit are available for this podcast. To claim credit, visit i3health.com/oda-EGFR-exon20-NSCLC. EGFR exon 20 insertion mutations are associated with a worse prognosis than other types of EGFR-mutant non-small cell lung cancer, or NSCLC. This episode of Oncology Data Advisor will focus on new developments in the diagnosis and treatment of NSCLC with EGFR exon 20 insertion mutations. It features perspectives from two noted experts in the field: Dr. Helena Yu, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center; and Dr. Maria Arcila, Director of the Diagnostic Molecular Pathology Laboratory at Memorial Sloan Kettering Cancer Center. This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Pathologists and lab professionals in global health are working to achieve health equity for all people worldwide. But what does that look like in practice? What challenges do global health advocates face, and what resources do they need to do their work? Which factors influence their ability to help build sustainable health delivery systems in places where people currently lack access to care? On this episode of Inside the Lab, our hosts Dr. Lotte Mulder and Dr. Dan Milner are joined by Dr. Beatriz Hornburg, MD, Anatomic Pathologist and Cofounder of the CEDAP Laboratory in South Brazil, Dr. Dianna Ng, MD, Assistant Attending Physician at Memorial Sloan Kettering, Ms. Linda Cherepow, HT(ASCP)HTL, Founder of Global Histology Consulting and Cofounder of Swift Path Solutions in Uganda, Dr. Jane Brock, MD, PhD, Chief of Breast Pathology at Brigham and Women’s Hospital, and Dr. Timothy Amukele, MD, VP Global Medical Director for ICON plc, to share their experiences with global training programs for pathologists and laboratory professionals. Our panelists discuss their concerns around realizing sustainable interventions, recruiting the right volunteers, and securing the resources they need to do effective work in global health.  Topics Covered  ·  Challenges around understanding culture, finding the right local partners, and realizing sustainable interventions·  Strategies for recruiting local and international volunteers and why it’s important to establish a standard of training for global health volunteers·  What diseases our panelists see as major threats to global health that need our attention ·  Virtual teaching in the COVID era and how travel restrictions have affected work in global health Connect with ASCPASCPASCP on FacebookASCP on Twitter Connect with Ms. Hornburg Ms. Hornburg on Twitter Connect with Dr. Ng Dr. Ng on Twitter Connect with Ms. Cherepow Ms. Cherepow on LinkedIn Connect with Dr. Brock Dr. Brock on Twitter Connect with Dr. Amukele Dr. Amukele on Twitter Connect with Dr. Milner & Dr. Mulder Dr. Milner on TwitterDr. Mulder on Twitter Resources Inside the Lab in the ASCP StoreWorld Health OrganizationWHO’s Global Initiative for Childhood CancerWHO’s Global Strategy to Accelerate the Elimination of Cervical CancerWHO’s Global Breast Cancer Initiative 

In this episode, Dillon and Dr. McElheny aka Dr. Kat, discuss early sports specialization vs long term athletic development models for youth athletes! Which model leads to greater likelihood of becoming an elite athlete? What are the risks/benefits of specializing early?   Dr. Kathryn McElheny is an Assistant Attending Physician at HSS. She is fellowship-trained and board certified in sports medicine and is the Non-operative Medical Director and Associate Team Physician for the New York Mets baseball team.   Her research focus has been on the use of strengthening in the prevention of overuse injuries experienced by novice marathon runners. She is also currently working on several studies evaluating injury incidence and prevention in professional and youth baseball players.   Dr. McElheny is committed to caring for athletes of all ages, levels and disciplines. In the context of her training and board certification in pediatrics, she is especially dedicated to managing injuries experienced by young athletes. In addition, she was a collegiate runner and is an avid baseball fan with a particular passion for treating runners and baseball athletes.   Enjoy!   -Team [P]Rehab   Learn More About Dr. Kathryn D. McElheny   Read Article: "Youth Athlete Sport Specialization – Train Like The Pros"   Link to Learn About [P]Rehab Programs   Link To Submit Questions/Topics   Visit our website: www.theprehabguys.com Follow us on: Instagram | Facebook | Youtube | Twitter   Connect with Team [P]Rehab info@theprehabguys.com     [P]Rehabbers thank you for listening and let us know what to talk about next. We hope to help you take control of your health through education! Did you enjoy this? Please rate, review, share, and subscribe. Every bit of feedback, comments, subscriptions, and sharing helps!!!  

Bile acid diarrhea is a common cause of diarrhea in patients with IBS and IBD. Currently, our diagnostic tools are unaccessible and often, therapeutic trials with bile acid sequestrants are used in the diagnosis. Dr Robert Battat shares his research with a new diagnostic marker, C4, in the diagnosis and management of B.A.D., leading to more targeted care for patients. Robert J. Battat, M.D. is an expert in inflammatory bowel disease specializing in Crohn's Disease and Ulcerative Colitis. He is an Assistant Attending Physician at the New York-Presbyterian Hospital/Weill Cornell Medicine and the Jill Roberts Center for Inflammatory Bowel Disease.     Dr. Battat obtained his medical degree and completed both his internal medicine residency training and clinical gastroenterology fellowship at McGill University in Montreal, Canada. He subsequently completed a clinical and research fellowship in inflammatory bowel disease at the University of California, San Diego and at Robarts Clinical Trials under Dr. William Sandborn and Dr. Brian Feagan.       He has a major interest in personalized medicine in inflammatory bowel disease and has extensively published scientific articles on this topic. This includes the development of a serum tess to diagnose bile acid malabsorption -which leads well into our topic today! Dr Battat and I discuss: What is bile acid diarrhea?  How does bile acid diarrhea develop? How is it diagnosed?  SEHCAT Test Therapeutic trial C4 Testing as a measurement for precursor to bile acids Is it a common cause of unexplained diarrhea in your practice? How is BAD managed?  Do you often see an overlap between BAD and IBS? IBD & BAD?  Where the research is going with BAD diagnosis and management and what can patients and health care providers expect? You can read Dr. Battat's research here: Battat, R., Duijvestein, M., Casteele, N. V., Singh, S., Dulai, P. S., Valasek, M. A., ... & Jain, A. (2019). Serum Concentrations of 7α-hydroxy-4-cholesten-3-one are Associated with Bile Acid Diarrhea in Patients with Crohn’s Disease. Clinical Gastroenterology and Hepatology, 17(13), 2722-2730.

Join host, Dr. Shannon O'Connor, as she interviews Dr. Alexander N. Shoushtari. Dr. Alexander Shoushtari is an Assistant Attending Physician and Clinical Director of the Melanoma Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medical College. He focuses exclusively on treating patients with melanoma using standard and developmental immune and targeted therapies. Within melanoma, his specific interests lie in developing treatments for non-cutaneous melanoma subtypes arising from the uveal tract in the eye, hands/feet, and mucosal surfaces. His early career work in uveal melanoma systemic therapy has been recognized by ASCO with a Young Investigator Award and AACR with a Junior Investigator Award.Tune in while Dr. Shoushtari and Dr. O'Connor discuss cancer treatment in the era of COVID along with Dr. Shoushtari's current research at Memorial Sloan Kettering Cancer Center.

Immunotherapy is a major class of therapy that continues to expand in the myeloma clinic. Dr. Alexander Leshokin of Memorial Sloan Kettering Cancer Center explains the various types of immunotherapies: transplant, monoclonal antibodies, bi-specific antibodies, antibody drug conjugates, cellular therapies like CAR T, vaccines and where each type of treatment is at in the various stages of development.  Dr, Alexander Lesokhin is Assistant Attending Physician at Memorial Hospital for Cancer and Allied Diseases and Assistant Member of Memorial Sloan Kettering Cancer Center. He is an active member of ASCO and ASH and has oversight of fellows and residents in the transplant, lymphoma and myeloma units. Dr. Lesokhin performs significant immunotherapy research and is engaged in studies to perform work in the lab that will bridge to the clinic as to why cancer cells can evade the bone marrow derived tumor-infiltrating cells. He is also performing research on checkpoint inhibitors and why T cells get exhausted, particularly following stem cell transplant.  Thanks to our episode sponsor, Celgene.   

On this episode of the Healthy, Wealthy and Smart Podcast, I welcome Dr. Ryan J. Lingor, MD and Michelle Cummings, PA on the show to discuss HSS Ortho Injury Care.  Dr. Lingor serves as an Assistant Attending Physician at Hospital of Special Surgery, faculty at Weill Cornell Medical College, Medical Director for HSS Ortho Injury Care, and Team Physician for the New York Rangers.  Michelle is a physician’s assistant who enjoys helping patients get back to their active lifestyles while also providing them with a thorough understanding of their orthopedic diagnosis. In this episode, we discuss: -The unique offerings of HSS Ortho Injury Care -Expanding patient’s access to quick and affordable medical care with the HSS Ortho Injury Care business model -How to market your services and gain trust with your community -And so much more!   Resources: HSS Ortho Injury Care   For more information on Dr. Lingor: Dr. Lingor serves as an Assistant Attending Physician at Hospital of Special Surgery, faculty at Weill Cornell Medical College, Medical Director for HSS Ortho Injury Care, and Team Physician for the New York Rangers.   Upon graduating from St. John's University in Minnesota, Dr. Lingor obtained certifications as a Registered Dietitian, Certified Athletic Trainer, and Strength and Conditioning Specialist. He went on to complete athletic training internships with the New England Patriots and Miami Dolphins and was named Head Athletic Trainer of NFL-Europe's Hamburg Sea Devils.   Dr. Lingor graduated from medical school at Loyola University Stritch School of Medicine and completed his residency in family medicine at Illinois Masonic in Chicago and his sports medicine fellowship at the University of Notre Dame. He is board certified in family medicine and obesity medicine with a subspecialty in sports medicine. His previous experience includes working as an Assistant Team Physician for the New York Jets as well several local high schools and colleges.   Having professional passions in weight management and comprehensive sports medicine, Dr. Lingor utilizes his background in nutrition, athletic training, and strength and exercise training to provide a comprehensive, personalized approach to help his patients achieve their health and performance goals.   At HSS, Dr. Lingor utilizes musculoskeletal ultrasound for diagnostic and therapeutic purposes, performs and conducts research on biological treatments for chronic tendon problems, provides comprehensive concussion management, and employs dry needling for muscle and tendon problems. He is active as a researcher and regularly presents at national conferences in primary care sports medicine.   Outside of medicine, he enjoys traveling, cooking, and being active outdoors, having competed in several marathons and three Ironman Triathlons, including the Hawaii Ironman World Championships.     For more information on Michelle: Michelle Cummings graduated magna cum laude from the University of South Carolina with an undergraduate degree in Exercise Kinesiology. During her studies, she spent three years as an undergraduate research assistant working on a study which focused on implementing health and nutrition programs into churches. Michelle then earned her Masters Degree in Physician Assistant Studies at the Massachusetts College of Pharmacy and Health Sciences. Prior to going to HSS, she worked as a PA for a private orthopedic and sports medicine practice focusing on upper extremity injuries. Michelle enjoys helping patients get back to their active lifestyles while also providing them with a thorough understanding of their orthopedic diagnosis. In her spare time, Michelle enjoys running, cycling, hiking, traveling, and crossword puzzles.   Read the full transcript below: Karen Litzy:                   00:01                Hi, Doctor Lingor and Michelle welcome to the podcast. I'm really happy to have you guys on today to talk about the HSS Ortho Injury Care. So thanks for coming on. Alright, so let’s sort of start from the beginning. All right, so what is the goal of this new clinic? What is the why behind it? Dr. Lingor:                    00:27                It just has always been a good place for orthopedic and sports medicine conditions. One of the problems that we've had at the hospital is getting appropriate access early on when patients need to be seen. So our providers tend to be pretty busy. So what we wanted to do is create a resource for patients to be able to go for their acute sports medicine and orthopedic needs. Karen Litzy:                   00:55                So that takes me to the next question is why sports medicine over other specialties? Obviously there was a hole to fill, right? So why this over others? Dr. Lingor:                    01:08                For myself, I really enjoyed helping keep people active and I think somebody’s activity correlates with their quality of life. And so if we can help, you know, people when they get injured or something to hold them back from, from being active on a daily basis, that's kind of where I wanted to help out. Michelle Cummings:      01:33                For me, It's two fold. One because I'm so passionate about sports in general and secondly, the specialty itself, you can actually make people better a lot quicker than in other specialties. So that's what drew me to sports. Karen Litzy:                                           I agree. I think with those sports injuries, I know coming from the physical therapist’s perspective, you kind of see this progression, right? So regardless of the age of the patient you kind of see from injury and you can really follow them through to recovery, which is really exciting from my standpoint and now, what are the commonly treated injuries seen in the clinic? Dr. Lingor:                    02:14                So we see all sorts of musculoskeletal injuries, the common stuff if somebody has a shoulder injury or just shoulder pain, we see a lot of knee injuries after athletic event, hip pain, all sorts. So any of the extremity injuries we do specialize in. And for patients that have back pain, fortunately we are a suited at HSS to have a back pain clinic. So we direct those patients to the right, the right place. Karen Litzy:                   02:47                And so why should a patient come to this Ortho care clinic versus going to the ER? What is the difference? Michelle Cummings:                              So the difference? Well, the ER you'll always have long wait times and they're not always apt to treat just orthopedic and sports injuries. So here we have an x ray onsite. Quick access to films as well as splinting and casting availability here. And what's Nice is you can actually schedule appointments online or call directly and we schedule same day and next day appointments. So if a patient sprains their ankle, you know, a night at basketball, they can go on and schedule an appointment early the next morning. So to try to shorten the wait time to the ER. Karen Litzy:                                           So you alluded a little bit to the splinting and casting, but you know, as non-operative clinicians, what types of conservative treatment are you providing for these patients as they come in? Dr. Lingor:                    03:49                So a lot of this stuff, you know, fortunately for us and most patients just don't want it to be checked out to see if they have something that they need to be more concerned about and kind of be directed in the right area. And fortunately we're kind of at a good position to give them access to all the resources that we have at the hospital for special surgery for those patients that need it. For stuff that we can take care of in the office here, we do have, as Michelle said, the x rays, we can do injections into different areas as necessary and we have the use of ultrasound to make sure that we are accurate with the injections and the care that we're providing. Karen Litzy:                   04:36                So this is how new? It's pretty new, right? When did you guys first open? Michelle Cummings:                              Yeah, we first opened in November of 2018 so it's been a couple of months now. Karen Litzy:                                           And as with everything new, every new venture, right, it has its ups and downs. So what are some of the challenges that have come up since this clinic opened? Dr. Lingor:                    05:02                Well, the biggest challenge is just getting our name out there and letting people know that we exist. We've been very fortunate to have a lot of interest both in our hospital and in the community to get people in the door when they need to be seen and get them moving in the right direction. So there's been a lot of positive energy that we've been able to benefit from in our first few months and we're still working out some kinks and not everything is smooth as you mentioned when you first get going. But, we've been very blessed to have a great staff around here that, that are all interested in, in doing what's best for the patient and providing exceptional patient care. Karen Litzy:                   05:46                And so you have some challenges, I'm sure there's also been some pros, right. So what have you found since opening the clinic have been a real positive or maybe even things you didn't even expect? Dr. Lingor:                    06:03                I think one of the nicest things is that our patients generally are in a pretty good mood when they come here because they're oftentimes patients, they're looking to go to the ER and they anticipate, you know, waiting for a couple hours and may have been told to follow up with her orthopedist at that time. And so patients are, excited when they come to a very reputable hospital and then being able to get an appointment the same day or the next day. And so they're pretty excited about that, about that opportunity. And so that's just kind of fun to work in that kind of environment where everyone is in a good mood off the bat. Karen Litzy:                   06:44                Yeah, that sounds amazing. And I would also have to think that, you know, when you go, if you have an orthopedic injury or like you said, it's soft tissue ortho injury and you go to the ER, you're not guaranteed to get an orthopedic specialist to treat you in the ER. Would you say that's correct. So is that how this kind of differs? Dr. Lingor:                    07:04                That's exactly right. If you go to the emergency room, they have the resources for, you know, taking care of the life threatening or really serious things. And that's perfectly appropriate for the ER because we don't treat those sorts of things. And with patients that go to the ER and have a lot more of the, you know, 90% of the orthopedic injuries where it's appropriate for us. And so this is a way for us to cut down on patient’s wait times and their costs as you know, an emergency room bill. Get them moving in the right direction right from the beginning. Karen Litzy:                   07:50                Do you guys take insurance? Michelle Cummings:                              It's actually listed on our website. So if a patient had questions about the insurances we take, it's all listed on the website, but we take all major insurances. Dr. Lingor:                    08:04                And that's pretty easy to find if you just Google HSS ortho injury care, you'll see it pops right up and you can see the insurances that we take and you can book yourself online and really booking an appointment is about a three minute process. Karen Litzy:                   08:19                Nice. And is this something that you patterned after? Like is there another clinic like this somewhere else in the country or is this one of a king clinics? Dr. Lingor:                    08:33                To our knowledge, this is one of the first ones in the region. I think a lot of other orthopedic places that have walk in clinics and stuff like that. I think this is the first stand alone clinic that operates, kind of how we do and you know, something we saw as a need and it's been a wildly successful in our first few months. Karen Litzy:                   09:01                Which is amazing. Dr. Lingor, I have a question for you. So aside from being an orthopedic physician, you also have a nutrition background, which I find really interesting. So are you able to infuse any of that within this clinic or do you see that as maybe something that you might want to infuse into in the future? Dr. Lingor:                    09:23                Well, with the sports medicine and medicine in general, being a field of nutrition in its other fields, it is something that I really enjoy learning about and trying to keep up with. In the clinic right now, it just helps me to better counsel patients and answer questions that they have, about nutrition and things that they can do to optimally heal and prevents some of the chronic conditions. And so I utilize it that way. And fortunately at HSS we do have a nutrition and dietetics team that we call upon as well as physicians who specialize in nutrition. We need more help. So it's not, I don't solely practice in the field of nutrition now, but kind of more as a complement to what we offer at the clinic. Karen Litzy:                   10:16                Yeah, I think that's great. Where do you see this going? Where do you see this, you know, that old question, where do you see this going in five years? Dr. Lingor:                    10:29                Yeah, so we're kind of looking at the hospital for special surgery as branching out to a couple of different other sites around the city, as well as a couple of places throughout the country in Las Vegas and in Florida. And so we're looking at kind of making this, you know, this being the flagship and then kind of model after the places just because it has seemed to do so well for our patients and for our physicians as well to get patients in. So by that I mean that when patients call other doctor's offices and they can't be seeing those to us, and then if necessary, then we get that patient back at an appointment that's a little bit more expedited then what the other physician would have been able to originally see them. Karen Litzy:                   11:26                Yeah. So you're sort of like, that patient could come in to you guys and if you feel like a referral is necessary, then you can kind of help streamline the process for the patient, which is amazing for patients because that's what they want. Because they come to you, they don't know what's going on. Dr. Lingor:                    11:41                Yeah, that's exactly right. And often times when they call one of our surgeons office, it may be a day at the surgeon just happens to be in the operating room and you know, regardless of how bad they want to see that patient, if they just don't have the ability to get them in. So, that's why I always say that we are here when the patient needs us and kind of get them moving in that right direction. Karen Litzy:                   12:01                And you know, and looking on the website, you have Michelle, a physician assistant and then a couple of other orthopedic physicians. How do you guys all kind of work together to make this clinic run? Michelle Cummings:                              Now that’s a good question. So Dr. Lingor is here more than anyone else as the medical director. So He's here usually five to six days of the week. We are closed on Sundays and I come in later in the morning and cover the night shifts and then we have the other providers that will cover sometimes on the Thursdays and also on Saturdays they cover in the need to fill in the gaps. Karen Litzy:                                           Got It. And this will be kind of like you said, your flagship operation and then hopefully kind of move this model throughout the country. I guess my question is from where you are now then from where you started, I mean, you obviously see this as something that's sustainable, right? Because I think a lot of people, when new things kind of move into their communities, there are always a little hesitant. What do you do for the community? And New York City's a big community, right? Like you said, getting the word out is part of it. But do you have any plans on kind of being part of like really being part of maybe even smaller communities, New York is gigantic, but really kind of getting into the community to get people to trust? Dr. Lingor:                    13:39                Yeah, I think that's really great point. And that's one of the things that just in our area, we're located on 65th street and second avenue. And so we see a lot of patients just in our area with, you know, a few block radius of patients walking by who have seen the signs a little bit and then come in and check it out to see what it is and say, Oh yeah, I have this knee issue. I wonder if you guys can take a look at it. We do welcome Walk-in's we prefer patients to make an appointment just to decrease their own waiting time. But we do see a lot of that and just providing that access to patients when they need it. I think has really helps build our name in our own little community that we serve right now. Karen Litzy:                   14:22                Yeah. I have my own practice and that's always the hardest thing, like you said, is getting the word out, letting people know you're there. What other marketing things, have you guys done that you've found successful so that if people are listening, they're like, wow, I really wish we had something like that in our community. Maybe they want to start it. What would your best advice be? Dr. Lingor:                    14:49                Well, one of the things that fortunately New York City has a plethora of is sporting events around being open during those times. So, like for instance, when the New York City Marathon is going on, you know, on that Sunday will be open that day to provide, access and for again, people in the area just to kind of get our name out a little bit more that people are walking by and having, you know, welcoming people in if they need to be seen by one of our providers that day and not, you know, that for the runners. Cause they're a little busy that day. Right? Yeah, exactly. Hopefully not too many of them. But we are just one block off the race course over the edge of some of those special events and volunteering with those groups. It's something we look forward to. Karen Litzy:                   15:48                Yeah. So kind of making partnerships within the community so they know you're there and they can refer to you and all that fun stuff. Dr. Lingor:                    15:56                Yeah. So we have several of our positions that do volunteer in past years with those events. And so we see when patients come in for the marathon Monday that they host after the New York City Marathon. Those patients, you know, they're seen by a medical professional that then if they need to get further testing done now we can provide that access to people. Karen Litzy:                   16:24                Fantastic. I mean, it sounds like you've got a great, a great niche over there and that you've definitely found a way to kind of plug that hole, right. You've found a way, you saw this sort of lack of accessibility and have made something a lot more accessible. So is there anything that we missed or anything that, you know, you want to the listeners to kind of remember about the clinic? Dr. Lingor:                    16:53                Yes. Things come up and unfortunately musculoskeletal injuries come up unexpectedly at the worst possible times. And there's a lot that can be done if when patients have that time of need, whether they're going on vacation or have a major life events. That's our primary goal is to provide access for the patients when they need it and help them sort through some of the frustrations. And difficulties that come along with musculoskeletal and sports injuries and you know, get them back to their level of health and quality of life that they're used to enjoying. Karen Litzy:                   17:38                Awesome. And Michelle, how about you? Anything that we didn't touch upon or any closing thoughts that you want to share? Michelle Cummings:                              No, I think just thank you for having us on the show and helping us get the word out. It's very helpful from different aspects to get out the word out in New York. So thank you for having us. Karen Litzy:                                           Yeah, you're welcome. And you know, I think it's also important, like now as a physical therapist, this is great for me to know because you know, we see patients directly now, so someone comes to me and I'm not sure, then for me it's great to say, Hey, there's a clinic that specializes in this. And then what it does for me is it kind of builds up my credibility with the patient because I'm sending them to a place where they're going to get the help that they need. Dr. Lingor:                    18:25                I’m very excited that physical therapists have the direct access, so through the physical therapy and find that, you know, the physical therapists that we commonly work with. It's been a great relationship with that. We look forward to expanding on that. And again, thank you very much. Karen Litzy:                   18:46                My pleasure. My pleasure. Thank you so much for coming on. So again, if you want to find out more information, you can go to hss.edu/ortho-injury-care. Is that right? Dr. Lingor:                    19:06                The easiest thing is just go to Google and type in Ortho injury care. Karen Litzy:                   19:14                Or you can go to podcast.healthywealthysmart.com and we'll have the link right there for you so you can just click on the link and go right to it. And hopefully we see more and more of these types of clinics popping up around the country because it certainly does fill a gap. So thank you guys for all that you do to help people with sports injuries, musculoskeletal injury. So thank you. And everyone, thanks so much for listening. Have a great couple of days and stay healthy, wealthy and smart.   Thanks for listening and subscribing to the podcast! Make sure to connect with me on twitter, instagram  and facebook to stay updated on all of the latest!  Show your support for the show by leaving a rating and review on iTunes!

Dr Shukla is an Assistant Professor of Research in Medicine at Weill Cornell Medical College and an Assistant Attending Physician at New-York Presbyterian Hospital. Dr Shukla’s clinical interests and expertise include management of obesity and related metabolic complications including type 2 diabetes. Dr Shukla obtained her medical degrees, MBBS and MD, from and completed internal medicine residency at Grant Medical College & J J Group of Hospitals in Mumbai, India. She subsequently trained in the UK as a senior house officer in Medicine, Specialist Registrar and Clinical Fellow in Endocrinology and as Registrar in Clinical Pharmacology in Australia over the next 5 years. While in the UK, she completed the training and examination requirements and was granted the MRCP(UK) degree. Dr. Shukla is currently the Director of Clinical Research at the Comprehensive Weight Control Center. A key area of Dr. Shukla’s research is a novel behavioral intervention, termed “food order,” for regulation of blood glucose in individuals with overweight /obesity, type 2 diabetes, and prediabetes In This Episode We Discuss Trials conducted examing the glycaemic response to food order “Carbohydrate-last meal pattern” Typical mixed meals where the components are not as easily separated Impact of fiber before ingestion of a main meal How these strategies compare to a protein pre-load Impact on ghrelin and GLP-1 How does all this research apply to real world recommendations for prediabetes and diabetes SNR LIVE: sigmanutrition.com/snr-live/

Mitchell Gaynor, M.D. is Founder and President of Gaynor Integrative Oncology, Assistant Attending Physician at New York Presbyterian Hospital/Weill Cornell Medical Center, and Clinical Assistant Professor of Medicine at Weill Medical College.  He has held the position of Director of Medical Oncology at The Strang Cancer Prevention Center where he still serves as a consultant.  He is also former Medical Director and Director of Medical Oncology at the Weill Cornell Medical Center Institute for Complementary and Integrative Medicine.  He has served on the Executive Review Panel at the Department of Defense – Alternative Medicine for Breast Cancer Sector and the Smithsonian Institute's Symposium on New Frontier in Breast Cancer and the Environment.  He is a frequent speaker and lecturer at hospitals, conferences, and universities throughout America and abroad.  He conducts on-going healing sessions for patients and families using meditation and chanting with Tibetan bowls.  Dr. Gaynor is also the best selling author of four books and a CD focusing on healing, health and the environment and cancer prevention.

Join us for our second interview on Myeloma Crowd Radio highlighting the new Myeloma Crowd Research Initiative on high-risk myeloma. As part of this series, Dr. Guenther Koehne, MD, PhD of the Memorial Sloan Kettering Cancer Center will share his use of a T cell vaccine with an allogeneic transplant to provide outstanding results, even in plasma leukemia patients. His research pulls out T cells, marks them with a tag to target the WT1 protein, and are given back. He will describe how this works, the impact he has seen so far, the stage of his clinical trial and the work left to do to make this an available therapy for high-risk myeloma patients.  Dr. Guenther Kohene, MD, PhD is Medical Director of the Cell Therapy Laboratory in the Bone Marrow Transplantation Laboratory at Sloan Kettering. He is also Assistant Member and Assistant Attending Physician in the Allogeneic Bone Marrow Transplantation Service. He is Assistant Professor of the Joan and Sanford Weill Medical College of Cornell University. He leads research at the BMT Department/Immunology Program to develop adoptive immunotherapeutic strategies for post-transplant blood disorders. He has particular expertise in the creation and monitoring of antigen-specific T cell responses in these patients. He is the Principal Investigator in active clinical trials using adoptive cell therapy following allogeneic stem cell transplants for multiple myeloma and plasma cell leukemia patients. He obtained his medical degree at the University of Hamburg, Germany and has been at Memorial Sloan Kettering Cancer Center permanently since 2005. Special thanks to our Myeloma Crowd Radio Episode sponsor, Takeda Oncology.

Marci Anne Goolsby, MD, Assistant Attending Physician in the HSS Women's Sports Medicine Center, presents on bone health and stress fractures in runners. Learn the most up-to-date information on avoiding painful fractures and make sure you are taking good care of your bones.

Marci Anne Goolsby, MD, Assistant Attending Physician in the HSS Women’s Sports Medicine Center presents on bone health and stress fractures in runners. Learn the most up-to-date information on avoiding painful fractures and make sure you are taking good care of your bones.